Germany · Delayed Price · Currency is EUR Nanobiotix Statistics
Total Valuation
Nanobiotix has a market cap or net worth of EUR 858.23 million. The enterprise value is 880.66 million.
| Market Cap | 858.23M |
| Enterprise Value | 880.66M |
Important Dates
The last earnings date was Thursday, November 20, 2025.
| Earnings Date | Nov 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +10.33% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 3.30% |
| Owned by Institutions (%) | 5.90% |
| Float | 30.86M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 84.48 |
| PB Ratio | -12.45 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -17.05 |
| EV / Sales | 86.69 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -27.84 |
Financial Position
The company has a current ratio of 0.63
| Current Ratio | 0.63 |
| Quick Ratio | 0.58 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.62 |
| Interest Coverage | -5.19 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -41.64% |
| Return on Invested Capital (ROIC) | -567.28% |
| Return on Capital Employed (ROCE) | 245.90% |
| Revenue Per Employee | 98,631 |
| Profits Per Employee | -501,388 |
| Employee Count | 108 |
| Asset Turnover | 0.15 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -37,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +456.29% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +456.29% |
| 50-Day Moving Average | 17.37 |
| 200-Day Moving Average | 7.70 |
| Relative Strength Index (RSI) | 46.70 |
| Average Volume (20 Days) | 21 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Nanobiotix had revenue of EUR 10.16 million and -51.64 million in losses. Loss per share was -1.09.
| Revenue | 10.16M |
| Gross Profit | 10.16M |
| Operating Income | -43.93M |
| Pretax Income | -51.68M |
| Net Income | -51.64M |
| EBITDA | -43.84M |
| EBIT | -43.93M |
| Loss Per Share | -1.09 |
Balance Sheet
The company has 28.82 million in cash and 51.24 million in debt, giving a net cash position of -22.42 million.
| Cash & Cash Equivalents | 28.82M |
| Total Debt | 51.24M |
| Net Cash | -22.42M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -68.95M |
| Book Value Per Share | -1.43 |
| Working Capital | -23.15M |
Cash Flow
In the last 12 months, operating cash flow was -31.13 million and capital expenditures -507,000, giving a free cash flow of -31.63 million.
| Operating Cash Flow | -31.13M |
| Capital Expenditures | -507,000 |
| Free Cash Flow | -31.63M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -432.39% |
| Pretax Margin | -508.71% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Nanobiotix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.33% |
| Shareholder Yield | -10.33% |
| Earnings Yield | -6.02% |
| FCF Yield | -3.69% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Nanobiotix has an Altman Z-Score of -2.82 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.82 |
| Piotroski F-Score | 1 |